$12.06
0.08% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$12.06
-1.07 8.15% 1M
-2.21 15.49% 6M
-2.84 19.06% YTD
-2.74 18.51% 1Y
-16.90 58.36% 3Y
-17.28 58.90% 5Y
-23.94 66.50% 10Y
NYSE, Closing price Fri, Dec 27 2024
+0.01 0.08%
ISIN
US28414H1032
Symbol
ELAN

Key metrics

Market capitalization $5.96b
Enterprise Value $9.83b
P/E (TTM) P/E ratio 29.52
EV/FCF (TTM) EV/FCF 25.87
EV/Sales (TTM) EV/Sales 2.21
P/S ratio (TTM) P/S ratio 1.34
P/B ratio (TTM) P/B ratio 0.91
Revenue growth (TTM) Revenue growth 1.92%
Revenue (TTM) Revenue $4.45b
EBIT (operating result TTM) EBIT $253.00m
Free Cash Flow (TTM) Free Cash Flow $380.00m
Cash position $490.00m
EPS (TTM) EPS $0.41
P/E forward 19.38
P/S forward 1.35
EV/Sales forward 2.22
Short interest 5.05%
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Elanco Animal Health, Inc. forecast:

10x Buy
63%
6x Hold
38%

Analyst Opinions

16 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
63%
Hold
38%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,454 4,454
2% 2%
100%
- Direct Costs 2,553 2,553
6% 6%
57%
1,901 1,901
3% 3%
43%
- Selling and Administrative Expenses 637 637
5% 5%
14%
- Research and Development Expense 342 342
4% 4%
8%
922 922
11% 11%
21%
- Depreciation and Amortization 669 669
3% 3%
15%
EBIT (Operating Income) EBIT 253 253
26% 26%
6%
Net Profit 205 205
118% 118%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
10 days ago
GREENFIELD, Ind. , Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P.
Neutral
PRNewsWire
19 days ago
SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a lawsuit is currently pending for certain investors in shares of Elanco Animal Health Incorporated (NYSE: ELAN). Long-Term investors who purchased shares of Elanco Animal Health Incorporated (NYSE: ELAN) prior to November 2023 and continue to hold any of those NYSE: ELAN shares also have certain options a...
Neutral
Business Wire
23 days ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Elanco is an “animal health company that develops, manufactures, and markets products for ...
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,800
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today